All In MedTech

FDA Clearance Tracker · P960007-S014

TRANSCYTE(TM)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 19, 2000 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 19, 2000

Approved

Time to decision

79 days

Received Mar 1, 2000. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P960007-S014
Device name
TRANSCYTE(TM)
Applicant location
San Diego, CA
Received
Mar 1, 2000
Decided
May 19, 2000
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P960007

Device type

Device class
Class III

Every decision under product code MGR

FDA's approval statement

As written in FDA's record.

APPROVAL TO CONDUCT THE FINAL PRODUCT STERILITY TEST IN-HOUSE UNDER THE CONDITIONS OF AN ISOLATOR ENVIRONMENT.

Source documents

Other decisions for Shire Regenerative Medicine

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.